Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1985 1
1994 1
1995 1
1996 2
2000 2
2003 1
2007 1
2010 4
2012 1
2013 3
2014 3
2016 2
2017 1
2018 1
2019 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

22 results

Results by year

Filters applied: . Clear all
Page 1
Response to R. Colebunders: Helminth infections in Nodding syndrome.
Spencer PS, Mazumder R, Palmer VS; Oregon-Uganda Research Team on Nodding Syndrome. Spencer PS, et al. J Neurol Sci. 2017 Jan 15;372:441. doi: 10.1016/j.jns.2016.10.010. Epub 2016 Oct 13. J Neurol Sci. 2017. PMID: 27765294 No abstract available.
Prednisone for the Prevention of Paradoxical Tuberculosis-Associated IRIS.
Meintjes G, Stek C, Blumenthal L, Thienemann F, Schutz C, Buyze J, Ravinetto R, van Loen H, Nair A, Jackson A, Colebunders R, Maartens G, Wilkinson RJ, Lynen L; PredART Trial Team. Meintjes G, et al. N Engl J Med. 2018 Nov 15;379(20):1915-1925. doi: 10.1056/NEJMoa1800762. N Engl J Med. 2018. PMID: 30428290 Free article. Clinical Trial.
Abdominal tuberculosis.
Colebunders R, Van Gompel A, De Vuyst H. Colebunders R, et al. Trans R Soc Trop Med Hyg. 1995 Mar-Apr;89(2):237-8. doi: 10.1016/0035-9203(95)90513-8. Trans R Soc Trop Med Hyg. 1995. PMID: 7778163 No abstract available.
Evaluation of the efficacy and tolerance of R 018893, R 089439 (loviride) and placebo in asymptomatic HIV-1-infected patients. Loviride Collaborative Study Group.
Staszewski S, Miller V, Kober A, Colebunders R, Vandercam B, Delescluse J, Clumeck N, Van Wanzeele F, De Brabander M, De Creé J, Moeremans M, Andries K, Boucher C, Stoffels P, Janssen PA. Staszewski S, et al. Antivir Ther. 1996 Jan;1(1):42-50. Antivir Ther. 1996. PMID: 11322258 Clinical Trial. No abstract available.
Strong association between the prevalence of bacterial vaginosis and male point-concurrency.
Kenyon CR, Colebunders R. Kenyon CR, et al. Eur J Obstet Gynecol Reprod Biol. 2014 Jan;172:93-6. doi: 10.1016/j.ejogrb.2013.10.011. Epub 2013 Oct 16. Eur J Obstet Gynecol Reprod Biol. 2014. PMID: 24183351
RESULTS: We found a strong relationship between the prevalence of male concurrency and BV prevalence (Pearson's R(2)=0.57; P=0.007). CONCLUSIONS: The findings of a strong ecological-level association between BV and partner concurrency need to be replicated and augmented wi …
RESULTS: We found a strong relationship between the prevalence of male concurrency and BV prevalence (Pearson's R(2)=0.57; P=0.007). …
Evaluation of Convalescent Plasma for Ebola Virus Disease in Guinea.
van Griensven J, Edwards T, de Lamballerie X, Semple MG, Gallian P, Baize S, Horby PW, Raoul H, Magassouba N, Antierens A, Lomas C, Faye O, Sall AA, Fransen K, Buyze J, Ravinetto R, Tiberghien P, Claeys Y, De Crop M, Lynen L, Bah EI, Smith PG, Delamou A, De Weggheleire A, Haba N; Ebola-Tx Consortium. van Griensven J, et al. N Engl J Med. 2016 Jan 7;374(1):33-42. doi: 10.1056/NEJMoa1511812. N Engl J Med. 2016. PMID: 26735992 Free PMC article. Clinical Trial.
Assessment of second-line antiretroviral regimens for HIV therapy in Africa.
Paton NI, Kityo C, Hoppe A, Reid A, Kambugu A, Lugemwa A, van Oosterhout JJ, Kiconco M, Siika A, Mwebaze R, Abwola M, Abongomera G, Mweemba A, Alima H, Atwongyeire D, Nyirenda R, Boles J, Thompson J, Tumukunde D, Chidziva E, Mambule I, Arribas JR, Easterbrook PJ, Hakim J, Walker AS, Mugyenyi P; EARNEST Trial Team. Paton NI, et al. N Engl J Med. 2014 Jul 17;371(3):234-47. doi: 10.1056/NEJMoa1311274. N Engl J Med. 2014. PMID: 25014688 Free article. Clinical Trial.
Long-term efficacy and safety of Raltegravir combined with optimized background therapy in treatment-experienced patients with drug-resistant HIV infection: week 96 results of the BENCHMRK 1 and 2 Phase III trials.
Steigbigel RT, Cooper DA, Teppler H, Eron JJ, Gatell JM, Kumar PN, Rockstroh JK, Schechter M, Katlama C, Markowitz M, Yeni P, Loutfy MR, Lazzarin A, Lennox JL, Clotet B, Zhao J, Wan H, Rhodes RR, Strohmaier KM, Barnard RJ, Isaacs RD, Nguyen BY; BENCHMRK Study Teamsa. Steigbigel RT, et al. Clin Infect Dis. 2010 Feb 15;50(4):605-12. doi: 10.1086/650002. Clin Infect Dis. 2010. PMID: 20085491 Free PMC article. Clinical Trial.
22 results